Myocardial Infarction News and Research

RSS

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

Hospital performance on publicly reported conditions may be correlated with overall mortality rates

Hospital performance on publicly reported conditions (acute myocardial infarction [heart attack], congestive heart failure, and pneumonia), may potentially be used as a signal of overall hospital mortality rates, according to a study by Marta L. McCrum, M.D., of Harvard School of Public Health, Boston, and colleagues.

25 Jun 2013

New ESC cardiac pacing and resynchronization guidelines presented at EHRA EUROPACE meeting

The 2013 ESC Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy- developed in collaboration with the European Heart Rhythm Association, have created a new classification system for bradyarrhythmias according to mechanisms rather than aetiology.

25 Jun 2013

Bristol-Myers Squibb and AstraZeneca announce top line results of Phase 4 SAVOR-TIMI-53 clinical trial of Onglyza

Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced top line results of the Phase 4 SAVOR-TIMI-53 (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) clinical trial of Onglyza ® (saxagliptin).

20 Jun 2013

Concerns raised about disproportionate impact of changes in hospital payment methods

Teaching hospitals with a higher intensity of physician-training activity achieve lower mortality rates, but higher hospitalization readmission rates for key medical diagnoses, reports a study in the July issue of Medical Care, published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

18 Jun 2013

Athera receives support from FP7 for development of fully human antibody PC-mAb

Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.

17 Jun 2013

Ischaemic heart disease patients at risk after 1 week of treatment

New study data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate a high prevalence of NSAID prescriptions in patients at risk of ischaemic heart disease.

14 Jun 2013

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

Viewpoints: Kasich on what would Reagan do about Medicaid; The need for more doctors

Leaders in the states that have decided against expanding (Medicaid) have often invoked Reagan conservatism as the reason to oppose extending Medicaid health care coverage to more people. After all, doesn't (Ronald) Reagan embody modern conservatism? He cut taxes, cut government red tape and fought the growth of entitlements. Yes, he did all those things. However, he also expanded Medicaid, not just once but several times (Ohio Gov. John Kasich, 6/2).

6 Jun 2013

New research shows uremic toxins increase heart attack risk

MD-Patients with advanced kidney disease who are undergoing hemodialysis are known to be highly susceptible to heart attacks and other cardiovascular complications, and now scientists likely know why.

31 May 2013

Study details Medicare spending variations

The analysis finds health differences explain as much as 85 percent of cost variations around the country.

30 May 2013

Researchers investigate preferences for participation in decision-making process among AMI patients

In a research letter, Harlan M. Krumholz, M.D., S.M., from Yale University School of Medicine and colleagues, "sought to investigate preferences for participation in the decision-making process among individuals hospitalized with an acute myocardial infarction ([AMI] or heart attack)."

28 May 2013

Study finds that inability to express emotions may cause delay in seeking attention

In case of heart attack it is of the most importance  to get immediate medical attention.

27 May 2013

New breakthrough in progeria treatment

Pharmaceuticals that inhibit a specific enzyme may be useful in treating progeria, or accelerated aging in children. A new study performed at the Sahlgrenska Academy, University of Gothenburg, Sweden, indicates that the development of progeria in mice was inhibited upon reducing the production of this enzyme.

21 May 2013

App could save lives by speeding treatment for heart attack

An experimental, inexpensive iPhone application transmitted diagnostic heart images faster and more reliably than emailing photo images, according to a research study presented at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions 2013.

18 May 2013

Elixir's DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark approval for its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System.

15 May 2013

Clinical study predicting risk of near-term MI and death in CAD patients to be published in JACC

FirstMark, a division of GenWay Biotech that is focused on developing and commercializing noninvasive diagnostic and health monitoring tests for unmet clinical needs, today announced that results from the break-through proof-of-concept clinical study, performed in collaboration with Emory University and MedStar Washington Hospital Center, will be published in the Journal of the American College of Cardiology.

9 May 2013

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration to initiate patient enrollment in the EXCELLA III clinical trial in the United States at up to 50 institutions with conditions to be addressed in parallel.

8 May 2013

Lowering door-to-balloon times helps benefit STEMI patients, study finds

While all heart attacks have the potential to be deadly, one type is referred to as the "widow maker" because of its high risk of death. A ST segment elevation myocardial infarction is a severe type of heart attack that occurs when a blockage in a coronary artery causes heart muscle to die; without prompt treatment risk of fatality increases dramatically. Coronary angioplasty, or percutaneous coronary intervention, is the most common emergency treatment for STEMI.

30 Apr 2013

Cardiac risk patients treated with beta-blockers have lower rates of mortality

Patients at elevated cardiac risk who were treated with beta-blockers on the day of or following noncardiac, nonvascular surgery had significantly lower rates of 30-day mortality and cardiac illness, according to a study in the April 24 issue of JAMA.

25 Apr 2013